Clinical Trial Update: Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. [Phase 4]

View source ↗

Summary

Pfizer's phase 4 study evaluated the safety of the 13-valent pneumococcal conjugate vaccine in preterm versus term infants, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: 13-valent Pneumococcal Vaccine, Premature Birth | Phase 4 | Status: COMPLETED | Results posted: 2015-02-04